@article{9792061a7f6c4a9d8a09b335db35c632,
title = "Multimodal 18F-AV-1451 and MRI findings in nonfluent variant of primary progressive aphasia: Possible insights on nodal propagation of tau protein across the syntactic network",
abstract = "Although abnormally folded tau protein has been found to self-propagate from neuron to connected neuron, similar propagation through human brain networks has not been fully documented. We studied tau propagation in the left hemispheric syntactic network, which comprises an anterior frontal node and a posterior temporal node connected by the white matter of the left arcuate fasciculus. This network is affected in the nonfluent variant of primary progressive aphasia, a neurodegenerative disorder with tau accumulation. Methods: Eight patients with the nonfluent variant of primary progressive aphasia (age, 67.0 ± 7.4 y; 4 women) and 8 healthy controls (age, 69.6 ± 7.0 y; 4 women) were scanned with 18F-AV-1451 tau PET to determine tau deposition in the brain and with MRI to determine the fractional anisotropy of the arcuate fasciculus. Normal syntactic network characteristics were confirmed with structural MRI diffusion imaging in our healthy controls and with blood oxygenation level-dependent functional imaging in 35 healthy participants from the Alzheimer Disease Neuroimaging Initiative database. Results: Language scores in patients indicated dysfunction of the anterior node. 18F-AV-1451 deposition was greatest in the 2 nodes of the syntactic network. The left arcuate fasciculus had decreased fractional anisotropy, particularly near the anterior node. Normal MRI structural connectivity from an area similar to the one containing tau in the anterior frontal node projected to an area similar to the one containing tau in the patients in the posterior temporal node. Conclusion: Tau accumulation likely started in the more affected anterior node and, at the disease stage at which we studied these patients, appeared as well in the brain region (in the temporal lobe) spatially separate from but most connected with it. The arcuate fasciculus, connecting both of them, was most severely affected anteriorly, as would correspond to a loss of axons from the anterior node. These findings are suggestive of tau propagation from node to connected node in a natural human brain network and support the idea that neurons that wire together die together.",
keywords = "Alzheimer dementia, F-AV-1451, PET/CT, Primary progressive aphasia, Prion propagation, Tau",
author = "Belen Pascual and Quentin Funk and Paolo Zanotti-Fregonara and Neha Pal and Elijah Rockers and Yu, {Meixiang Max} and Bryan Spann and Rom{\'a}n, {Gustavo C.} and Schulz, {Paul E.} and Christof Karmonik and Appel, {Stanley H.} and Masdeu, {Joseph C.}",
note = "Funding Information: Meixiang Yu and Joseph Masdeu received research funding from Eli Lilly, parent company of Avid Radiopharmaceuticals, manufacturer of 18F-AV-1451. Paolo Zanotti-Fregonara and Joseph Masdeu are on a speaker bureau for Eli Lilly. The study was funded by the Chao, Graham, Harrison, and Nantz Funds from the Houston Methodist Foundation. Avid Radiopharmaceuticals provided the 18F-AV-1451 precursor free of charge. The ADNI data used in this study was collected and shared through a project, ADNI, funded by the National Institutes of Health (grant U01 AG024904) and DOD (Department of Defense award W81XWH-12-2-0012). The ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and generous contributions from the following: AbbVie, Alzheimer{\textquoteright}s Association; Alzheimer{\textquoteright}s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Euro-Immun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (https://fnih.org/). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer{\textquoteright}s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. No other potential conflict of interest relevant to this article was reported. Publisher Copyright: COPYRIGHT {\textcopyright} 2020 by the Society of Nuclear Medicine and Molecular Imaging.",
year = "2020",
month = feb,
day = "1",
doi = "10.2967/jnumed.118.225508",
language = "English (US)",
volume = "61",
pages = "263--269",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "2",
}